136 related articles for article (PubMed ID: 22492091)
1. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.
Xiao C; Bandsma RH; Dash S; Szeto L; Lewis GF
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1513-9. PubMed ID: 22492091
[TBL] [Abstract][Full Text] [Related]
2. Effects of Intranasal Insulin on Triglyceride-Rich Lipoprotein Particle Production in Healthy Men.
Xiao C; Dash S; Stahel P; Lewis GF
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1776-1781. PubMed ID: 28751575
[TBL] [Abstract][Full Text] [Related]
3. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.
Dash S; Xiao C; Morgantini C; Szeto L; Lewis GF
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2895-901. PubMed ID: 24072699
[TBL] [Abstract][Full Text] [Related]
4. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
5. Intravenous Glucose Acutely Stimulates Intestinal Lipoprotein Secretion in Healthy Humans.
Xiao C; Dash S; Morgantini C; Lewis GF
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1457-63. PubMed ID: 27150393
[TBL] [Abstract][Full Text] [Related]
6. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes.
Nogueira JP; Maraninchi M; Béliard S; Padilla N; Duvillard L; Mancini J; Nicolay A; Xiao C; Vialettes B; Lewis GF; Valéro R
Arterioscler Thromb Vasc Biol; 2012 Apr; 32(4):1039-44. PubMed ID: 22308041
[TBL] [Abstract][Full Text] [Related]
7. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
[TBL] [Abstract][Full Text] [Related]
8. Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans.
Padilla N; Maraninchi M; Béliard S; Berthet B; Nogueira JP; Wolff E; Nicolay A; Bégu A; Dubois N; Grangeot R; Mattei C; Vialettes B; Xiao C; Lewis GF; Valéro R
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2330-7. PubMed ID: 25104797
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
10. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans.
Duez H; Lamarche B; Uffelman KD; Valero R; Cohn JS; Lewis GF
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1357-63. PubMed ID: 16614317
[TBL] [Abstract][Full Text] [Related]
11. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia.
Bandsma RH; Lewis GF
Atherosclerosis; 2010 Sep; 212(1):40-1. PubMed ID: 20638063
[No Abstract] [Full Text] [Related]
12. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the beneficial and protective effects of exenatide in diabetic rats.
Lotfy M; Singh J; Rashed H; Tariq S; Zilahi E; Adeghate E
J Endocrinol; 2014 Mar; 220(3):291-304. PubMed ID: 24353307
[TBL] [Abstract][Full Text] [Related]
14. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
15. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
[TBL] [Abstract][Full Text] [Related]
16. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
17. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
[TBL] [Abstract][Full Text] [Related]
18. New and emerging regulators of intestinal lipoprotein secretion.
Xiao C; Dash S; Morgantini C; Lewis GF
Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456
[TBL] [Abstract][Full Text] [Related]
19. Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome.
Tushuizen ME; Pouwels PJ; Bontemps S; Rustemeijer C; Matikainen N; Heine RJ; Taskinen MR; Diamant M
Atherosclerosis; 2010 Jul; 211(1):308-14. PubMed ID: 20227695
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
